The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard, the first FDA-approved multitarget stool DNA test, has been available since 2014.1
COLORECTAL CANCER SCREENING — Guidelines recommend screening average-risk adults for CRC beginning at age 45. Colonoscopy is generally the preferred method of screening; it can detect precancerous adenomas and allows for biopsy and removal of lesions during the procedure. Fecal immunochemical...
- Drugs for Open-Angle Glaucoma
- A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
- In Brief: Epinephrine 1 mg Nasal Spray (neffy)
- In Brief: A New Indication for Tenecteplase (TNKase)
- Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
- Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)
RELEASE
According to the Centers for Disease Control (CDC), as of April 24 there have been 844 confirmed cases of measles in the US in 2025; 11% of cases have resulted in hospitalization and 3 patients have died. The majority of cases (96%) have been in unvaccinated persons or in those whose vaccination history was unknown.1
TRANSMISSION — The measles virus can be transmitted by direct contact with or airborne exposure to infectious droplets. Importation of measles by international travelers has led to outbreaks in the US, primarily in unvaccinated persons.
RECOMMENDATIONS — No antiviral drugs have been approved by the FDA for treatment or prevention of measles. The live-attenuated MMR (measles, mumps, rubella) vaccine [or the MMRV (measles, mumps, rubella, varicella) vaccine in children 12 months-12 years old], offers the best protection against measles; one dose is 93% and two doses are 97% …